» Articles » PMID: 35646285

Gut Microbiome in Non-alcoholic Fatty Liver Disease Associated Hepatocellular Carcinoma: Current Knowledge and Potential for Therapeutics

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) are rising in incidence and are an increasingly common cause of cirrhosis and hepatocellular carcinoma (HCC). The gut microbiome is closely connected to the liver the portal vein, and has recently been identified as a predictor of liver disease state. Studies in NAFLD, cirrhosis and HCC have identified certain microbial signatures associated with these diseases, with the disease-associated microbiome changes collectively referred to as dysbiosis. The pathophysiologic underpinnings of these observations are an area of ongoing investigation, with current evidence demonstrating that the gut microbiome can influence liver disease and carcinogenesis effects on intestinal permeability (leaky gut) and activation of the innate immune system. In the innate immune system, pathogen recognition receptors (Toll like receptors) on resident liver cells and macrophages cause liver inflammation, fibrosis, hepatocyte proliferation and reduced antitumor immunity, leading to chronic liver disease and carcinogenesis. Dysbiosis-associated changes include increase in secondary bile acids and reduced expression of FXR (nuclear receptor), which have also been associated with deleterious effects on lipid and carbohydrate metabolism associated with progressive liver disease. Longitudinal experimental and clinical studies are needed in different populations to examine these questions further. The role of therapeutics that modulate the microbiome is an emerging field with experimental studies showing the potential of diet, probiotics, fecal microbiota transplantation and prebiotics in improving liver disease in experimental models. Clinical studies are ongoing with preliminary evidence showing improvement in liver enzymes and steatosis. The microbial profile is different in responders to cancer immunotherapy including liver cancer, but whether or not manipulation of the microbiome can be utilized to affect response is being investigated.

Citing Articles

Aluminum-induced oxidative stress promotes changes in the structure of the gut microbiota and liver deficiency.

Feng R, Chen L, Yang M Heliyon. 2024; 10(16):e36165.

PMID: 39224282 PMC: 11367489. DOI: 10.1016/j.heliyon.2024.e36165.


Role of Gut Microbial Metabolites in the Pathogenesis of Primary Liver Cancers.

Pallozzi M, De Gaetano V, Di Tommaso N, Cerrito L, Santopaolo F, Stella L Nutrients. 2024; 16(14).

PMID: 39064815 PMC: 11280141. DOI: 10.3390/nu16142372.


Role of circular RNAs and gut microbiome in gastrointestinal cancers and therapeutic targets.

Abdullah S, Abdullah S, Hussen B, Younis Y, Rasul M, Taheri M Noncoding RNA Res. 2024; 9(1):236-252.

PMID: 38192436 PMC: 10771991. DOI: 10.1016/j.ncrna.2023.12.002.


Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: The Next Threat after Viral Hepatitis.

Salaheldin M, Aly H, Lau L, Afify S, El-Kassas M Diagnostics (Basel). 2023; 13(16).

PMID: 37627890 PMC: 10453181. DOI: 10.3390/diagnostics13162631.


Crosstalk between Gut Microbiota and Host Immunity: Impact on Inflammation and Immunotherapy.

Campbell C, Kandalgaonkar M, Golonka R, Yeoh B, Vijay-Kumar M, Saha P Biomedicines. 2023; 11(2).

PMID: 36830830 PMC: 9953403. DOI: 10.3390/biomedicines11020294.


References
1.
Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A . Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab. 2017; 25(5):1054-1062.e5. PMC: 5502730. DOI: 10.1016/j.cmet.2017.04.001. View

2.
Rau M, Rehman A, Dittrich M, Groen A, Hermanns H, Seyfried F . Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease. United European Gastroenterol J. 2018; 6(10):1496-1507. PMC: 6297934. DOI: 10.1177/2050640618804444. View

3.
Bomhof M, Parnell J, Ramay H, Crotty P, Rioux K, Probert C . Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial. Eur J Nutr. 2018; 58(4):1735-1745. DOI: 10.1007/s00394-018-1721-2. View

4.
Safari Z, Gerard P . The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). Cell Mol Life Sci. 2019; 76(8):1541-1558. PMC: 11105223. DOI: 10.1007/s00018-019-03011-w. View

5.
Massarweh N, El-Serag H . Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control. 2017; 24(3):1073274817729245. PMC: 5937247. DOI: 10.1177/1073274817729245. View